News
Eli Lilly says weight loss pill leads to 12 percent more weight loss
Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval. Patients taking the pill called orforglipron, an oral GLP-1 receptor, lost almost 12% of their body weight,
Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
1don MSN
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Eli Lilly (LLY) recently introduced EBGLYSS through Senderra Specialty Pharmacy, targeting patients with atopic dermatitis, while enhancing patient and provider experiences via SenderraCare+. Despite ...
The iPhone maker's shares [rallied for a second day]( ...
The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback